Avi Biopharma Inc - Current report filing (8-K)
September 19 2008 - 2:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported):
September 18, 2008
AVI BioPharma, Inc.
(Exact name of Company as specified in its
charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File No.)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification No.)
|
incorporation)
|
|
|
|
|
One S.W.
Columbia, Suite 1105
Portland,
OR 97258
(Address of principal executive offices)
(503)
227-0554
Registrants telephone number, including area
code
Not
Applicable
(Former name or former address, if changed
since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o
|
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.02
Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On
September 18, 2008, Alan P. Timmins was terminated without cause as President
and Chief Operating Officer of AVI BioPharma, Inc. (the Company).
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Portland, State of Oregon, on September 19, 2008.
|
AVI
BioPharma, Inc.
|
|
|
|
|
By:
|
/s/ LESLIE
HUDSON, Ph.D.
|
|
|
Leslie
Hudson, Ph.D.
|
|
|
Chief
Executive Officer
|
|
|
(Principal
Executive Officer)
|
2
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024